Tuesday, November, 19, 2019 08:26:51

Pfizer’s inhibitor drug given Breakthrough Therapy designation by FDA

Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …

Microsoft introduces hi-tech glasses that monitor blood pressure

Software behemoth Microsoft is reportedly developing technologically advanced spectacles that incessantly monitor blood pressure all day, in a bid to reduce the risk of strokes and heart attacks. According to sources familiar with the development, these spectacles are presumed to have in-built hidden sensors at …

CHAOS approach taps CRISPR to alter multiple genes in bacterial cells

Researchers at the University of Colorado Boulder have reportedly developed an unconventional genetic disruption strategy that successfully stymies the growth of antibiotic-resistant bacteria, giving scientists an edge over deadly superbugs. According to data from the Centers for Disease Control, these multiple drug resistant pathogens — …

Pfizer brings the development of DMD candidate Domagrozuma to a halt

Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …

Alibaba unveils online service for doctor consultation, meds delivery

Alibaba, the Chinese multinational giant, has recently launched an online medical consultation and 24-hour medicine delivery service on its Taobao marketplace platform. As per sources familiar with the matter, users can now seek urgent medical attention or medications whenever required, and over-the counter medicines ordered …

AstraZeneca phase III lupus-drug trial fails to meet primary goal

AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …

Voluntis & AstraZeneca advance collaboration in the field of oncology

Voluntis, a medical intelligence firm that develops advanced digital therapeutics to enhance medications and medical devices, has reportedly announced to extend its collaboration with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, in a bid to advance oncology treatment technology. The new agreement states that the …